Exclusive deal hands Immunis rights to advance TRK-820 for L-dopa-induced dyskinesia across the US and Europe.
There is a particular kind of frustration that shadows Parkinson’s disease. Not just the tremors or stiffness, but the trade-offs. The medicine that restores movement can, over time, distort it.
This week, Japanese company Toray Industries, Inc announced it has entered an exclusive licensing agreement with Immunis, Inc for a drug candidate designed to tackle one of Parkinson’s most disruptive complications: dyskinesia caused by long-term L-dopa use [1].
The candidate, previously known as TRK-820 (generic name: Nalfurafine Hydrochloride), will now move forward under the name IMM02-KORA. Immunis gains exclusive rights to develop and commercialize the therapy in the United States, Canada, the European Union and the European Free Trade Association. Toray will receive upfront and milestone payments tied to development, as well as royalties if the drug reaches the market. This is a standard biotech licensing deal, but the clinical and longevity implications run deeper.
Parkinson’s disease is a progressive brain disorder that damages dopamine-producing neurons. Dopamine helps regulate movement – think of it as the brain’s internal signal that keeps motion smooth and coordinated.
For decades, L-dopa has been the backbone of treatment. It acts as a precursor to dopamine, helping replenish what the brain can no longer produce. For many patients, it can be life-changing. But over time, the story often shifts.
According to 2022 data from the World Health Organization (WHO), Parkinson’s prevalence has doubled over the past 25 years, with more than 8.5 million people living with the disease as of 2019. As patients remain on L-dopa longer, many develop dyskinesia – involuntary, sometimes jerky movements that can be socially and physically debilitating.
Imagine finally regaining control of your body, only to find it moving unpredictably again. Not from disease progression alone, but as a side effect of the very drug meant to help. This is the problem IMM02-KORA is designed to address: L-dopa-induced dyskinesia.
TRK-820 is described as the world’s first selective opioid kappa receptor agonist discovered by Toray. That phrase may sound technical, but the concept is straightforward.
Most Parkinson’s therapies revolve around dopamine – boosting it, mimicking it or preserving it. TRK-820 works differently. It targets a specific brain receptor, the kappa opioid receptor, which modulates neural signaling.
If dopamine is the fuel that keeps the engine running, dyskinesia is what happens when the wiring starts misfiring. Instead of pouring in more fuel, this approach attempts to adjust the circuitry itself, calming the abnormal signaling patterns that contribute to involuntary movement. That shift in strategy is what makes the program notable. It is moving beyond simply replacing missing chemicals and toward fine-tuning complex neural networks.
In February 2026, Immunis submitted an Investigational New Drug application to the US Food and Drug Administration to initiate a Phase I clinical trial. The first step will focus on safety, an early but essential milestone.
Parkinson’s is not just a neurological condition; it is profoundly age-associated. As populations live longer, the number of people at risk continues to rise. Longevity is often framed around breakthrough technologies – gene editing, cellular reprogramming, regenerative medicine. But there is another side to the equation: managing chronic diseases better and preserving quality of life over decades.
Dyskinesia can limit independence, complicate caregiving and reduce social participation. If IMM02-KORA can meaningfully reduce those involuntary movements without diminishing L-dopa’s benefits, it could extend functional years for patients.
For Toray, the move aligns with its open-innovation strategy. The company continues to concentrate research resources on its proprietary drug discovery technologies while partnering externally to accelerate development.
Meanwhile, Immunis is a clinical-stage biotech focused on therapies that address underlying drivers of aging, particularly in muscle and metabolic disease. Its broader mission centers on maximizing health span and minimizing disease.
There is an important convergence here. A company known for aging biology stepping into neurodegeneration reflects a growing recognition: aging is not a collection of isolated diseases, but a network of interrelated vulnerabilities.
Licensing TRK-820 may also signal a pragmatic shift in biotech. Rather than chasing only novel molecular entities, companies are increasingly revisiting known compounds with fresh mechanistic insight. Sometimes innovation is less about inventing from scratch and more about reframing what already exists.
Of course, the road from Phase I to approval is long and uncertain. Many promising neurological candidates falter in later-stage trials. Caution is warranted, but so is optimism.
If we are serious about extending health span, we cannot ignore the lived realities of aging-related diseases. Addressing treatment-induced complications like dyskinesia may not grab headlines the way radical life-extension technologies do. Yet for millions of families, smoothing those complications could mean the difference between dependence and autonomy.
[1] https://www.toray.com/news/article.html?contentId=k75l0132
